PharmaCyte Biotech Inc
PMCB
NASDAQ
Biotechnology
$0.55
USD
0.00 (+0.18%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $5.90M
Volume 131.5K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-19.42M
TTM
-163.4%
YoY
Operating Cash Flow
$-5.15M
TTM
-73.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 0.9 | 0.8 | 1.2 | 2.0 | 4.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 1.5 |
Total Operating Expenses | 1.0 | 0.8 | 1.4 | 2.1 | 5.9 |
Operating Income | -1.0 | -0.8 | -1.4 | -2.1 | -5.9 |
EBITDA | -1.0 | -0.8 | -1.4 | -2.1 | -4.3 |
Other Income / Expense | 12.6 | -7.7 | -6.2 | 2.6 | -11.3 |
Total Other Income / Expense | 12.8 | -7.5 | -6.0 | 2.9 | -10.5 |
Income Before Income Taxes | 11.7 | -8.4 | -7.4 | 0.7 | -16.4 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | 11.7 | -8.4 | -7.4 | 0.7 | -4.4 |
Consolidated Net Income / Loss | 11.7 | -8.4 | -7.4 | 0.7 | -16.4 |
Net Income Attributable to Common Shareholders | 10.8 | -8.4 | -8.4 | -1.6 | -20.2 |
Basic EPS | $1.75 | -$1.23 | -$1.24 | -$0.17 | -$1.89 |
Diluted EPS | $1.75 | -$1.23 | -$1.24 | -$0.17 | -$1.89 |
Basic Shares Outstanding | 6.2M | 6.8M | 6.8M | 9.3M | 10.7M |
Diluted Shares Outstanding | 6.2M | 6.8M | 6.8M | 9.3M | 10.7M |